Adelaide SA / Inverness Medical Innovations Inc / PURPOSE AND TARGET GROUP / /
Country
Australia / New Zealand / /
Currency
AUD / USD / /
Event
FDA Phase / /
Facility
University of Adelaide / /
Holiday
Commonwealth Day of Australia / /
IndustryTerm
immediate processing / health technology / suitable tool / literature search / subsequent improvements health technologies / /
MedicalCondition
urinary tract disease / bladder transitional cell carcinoma / cancer / post-operative cancer / NMP22 bladder cancer / disease / unrelated urological diseases / transitional cell carcinoma / bladder cancer / tumour / bladder markers Bladder cancer / protein tumor / carcinoma / superficial urothelial carcinoma / primary cancer / injury / urinary tract infections / urinary bladder cancer II / further cancers / muscle-invasive tumours / histologically confirmed cancer / tumours / /
MedicalTreatment
catheters / /
Organization
Health Policy Advisory Committee on Technology / National Science Foundation / National Horizon Scanning Unit / School of Population Health and Clinical Practice / Commonwealth Copyright Administration / University of Adelaide / Adelaide / Department of Health / Australian Health Ministers’ Advisory Council / Medical Services Advisory Committee / Attorney General’s Department / United States Food and Drug Administration / Medicare / /
Person
Janet Hiller / Linda Mundy / Schroeder / / /
Position
experienced pathologist / Governor / Professor / /
Product
BladderChek® / BladderChek / /
ProvinceOrState
Connecticut / /
Technology
health technology / cancer detection / 000150 NAME OF TECHNOLOGY / antibodies / hybridization / subsequent improvements health technologies / Horizon Scanning Technology / /
Horizon Scanning Technology Prioritising Summary NMP22 BladderChek Diagnostic test for bladder cancer Update: November 2009